Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Non-Hodgkin's LymphomaMantle Cell Lymphoma
Interventions
DRUG

Bendamustine

Bendamustine at 90 mg/m\^2 IV on Days 1 and 2 of a 28-day cycle.

DRUG

Rituximab

Rituximab at 375 mg/m\^2 IV on Day 1 of a 28-day cycle.

Trial Locations (43)

Unknown

Hematology Oncology Physicans Extenders Group, Tucson

University of Arkansas for Medical Sciences, Little Rock

St. Jude Heritage Medical Group, Fullerton

Comprehensive Cancer Center, Palm Springs

University of Colorado Cancer Center, Aurora

Rocky Mountain Cancer Center, Denver

The Hospital of Central Connecticut, New Britain

Cancer Center of Central Connecticut, Southington

Memorial Cancer Institute, Hollywood

Cancer Centers of Florida, Orlando

MD Anderson Cancer Cnt Orlando, Orlando

John B Amos Cancer Center, Columbus

St Francis Cancer Research Foundation, Beech Grove

Cedar Valley Medical Specialists, Waterloo

Cancer Center of Kansas, Wichita

University of Kentucky, Lexington

LSU Health Sciences Center - Shreveport, Shreveport

MaineGeneral Medical Center, Augusta

Missouri Cancer Associates, Columbia

Kansas City Cancer Center, Kansas City

UNM Cancer Center/New Mexico Cancer Care Alliance, Albuquerque

Interlakes Foundation, Inc, Rochester

SUNY Upstate / Upstate Medical University, Syracuse

Willamette Valley Cancer Center, Springfield

Geisinger Medical Center, Danville

Pennsylvania Oncology Hematology Associates, Inc., Philadelphia

Charleston Hematology Oncology, PA, Charleston

Sarah Cannon Cancer Center, Nashville

Texas Oncology, P.A., Fort Worth

Cancer Care Center of South Texas, San Antonio

Texas Oncology, Tyler

Virginia Oncology Associates, Norfolk

Cancer Outreach Asscociates, PC, Richlands

Cancer Care Northwest-South, Spokane

Northwest Cancer Specialists, PC, Vancouver

West Virginia University School of Medicine, Morgantown

The Canberra Hospital, Garran

Royal Adelaide Hospital, Adelaide

The Queen Elizabeth Hospital, Woodville

Royal Hobart Hospital, Hobart

The Alfred Hospital, Melbourne

Queen Elizabeth II Health Sciences Centre, Halifax

Ottawa Hospital - General Campus, Ottawa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY

NCT01073163 - Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) | Biotech Hunter | Biotech Hunter